Balakrishna S, Song W, Achanta S, Doran SF, Liu B, Kaelberer MM, et al. TRPV4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2014;307:L158-72.
Bannerman DD, Sathyamoorthy M, Goldblum SE. Bacterial Lipopolysaccharide Disrupts Endothelial Monolayer Integrity and Survival Signaling Events through Caspase Cleavage of Adherens Junction Proteins. J Bio Chem. 1998;273:35371-80.
Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A,et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016;315:788-800.
Bosmann M, Russkamp NF, Ward PA. Fingerprinting of the TLR4-induced acute inflammatory response. Exp Mol Pathol. 2012;93:319-23.
Brooks CA, Barton LS, Behm DJ, Eidam HS, Fox RM, Hammond M, et al. Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4). ACS Med Chem Lett. 2019;10:1228-1233.
Dalsgaard T, Sonkusare SK, Teuscher C, Poynter ME, Nelson MT. Pharmacological inhibitors of TRPV4 channels reduce cytokine production, restore endothelial function and increase survival in septic mice. Sci Rep. 2016;6:338-41.
Erfinanda L, Lin Z, Gutbier B, Reppe K, Lienau J, Hocke A, et al. Loss of CFTR causes endothelial barrier failure in pneumonia via inhibition of WNK1 and TRPV4 activation. Eur Resp J. 2017;50:PA1874.
Gandhirajan RK, Meng S, Chandramoorthy HC, Mallilankaraman K, Mancarella S, Gao H, et al. Blockade of NOX2 and STIM1 signaling limits lipopolysaccharide-induced vascular inflammation. J Clin Invest. 2013;123:887-902.
Glenn MS, Johnson BD, Sprecher DL, Reddy YNV, Obokata M, Goldsmith S, et al. Targeting Pulmonary Capillary Permeability to Reduce Lung Congestion in Heart Failure: A Randomized, Controlled Pilot Trial. Eur J Heart Fail. In Press.
Goyal N, Skrdla P, Schroyer R, Kumar S, Fernando D, Oughton A, et al. Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects. Am J Cardiovasc Drugs. 2019;19:335-342.
Günther A, Siebert C, Schmidt R, Ziegler S, Grimminger F, Yabut M et al. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med. 1996;153:176-84.
Hamanaka K, Jian MY, Weber DS, Alvarez DF, Townsley MI, Al-Mehdi AB,et al. TRPV4 initiates the acute calcium-dependent permeability increase during ventilator‑induced lung injury in isolated mouse lungs. Am J Physiol Lung Cell Mol Physiol. 2007;293:L923-32.
Hamanaka K, Jian MY, Townsley MI, King JA, Liedtke W, Weber DS, et al. TRPV4 channels augment macrophage activation and ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2010; 299:L353-62.
Hernandez ML, Mills K, Almond M, Todoric K, Aleman MM, Zhang H, et al. IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers. J Allergy Clin Immunol. 2015;135:379-85.
Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M, Schaumann F, Mueller M, Bredenbroeker D, et al. Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2008;21:616-23.
Holz O, Tan L, Schaumann F, Müller M, Scholl D, Hidi R, et al. Inter- and intrasubject variability of the inflammatory response to segmental endotoxin challenge in healthy volunteers. Pulm Pharmacol Ther. 2015;35:50-9.
Hughes S, Cuffe RL, Lieftucht A, Garrett Nichols W. Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial. Pharm Stat. 2009;8:25–37.
Janssen O, Schaumann F, Holz O, Lavae-Mokhtari B, Welker L, Winkler C, et al. Low-dose endotoxin inhalation in healthy volunteers--a challenge model for early clinical drug development. BMC Pulm Med. 2013;13:19.
Ludbrook V, Hanrott K, Kreindler J, Marks-Konczalik J, Bird N, Hewens D, et al. Abstract S27: A placebo‑controlled, double‑blind, randomised, crossover study to assess the efficacy, safety and tolerability of TRPV4 inhibitor GSK2798745 in participants with chronic cough (BTS winter meeting 2019). Thorax. 2019;74(Suppl 2):A1-A262,
Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest. 2012;122:2731-40.
Matthay MA, McAuley DF, Ware LB. Clinical trials in acute respiratory distress syndrome: challenges and opportunities. Lancet Respir Med. 2017;5:524-34.
Michel O, Dentener M, Cataldo D, Cantinieaux B, Vertongen F, Delvaux C, et al. Evaluation of oral corticosteroids and phosphodiesterase-4 inhibitor on the acute inflammation induced by inhaled lipopolysaccharide in human. Pulm Pharmacol Ther. 2007;20:676-83.
Morty RE, Kuebler WM. TRPV4: an exciting new target to promote alveolocapillary barrier function. Am J Physiol Lung Cell Mol Physio. 2014;307:L817-21.
Rennard SI, Basset G, Lecossier D, O’Donnell KM, Pinkston P, Martin PG, Crystal RG. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol. 1986;60:532-8.
Rodvold KA, George JM, Yoo L. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet. 2011;50:637-64.
Rodvold KA, Gotfried MH, Still JG, Clark K, Fermandes P. Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects. Antimicrob Agents Chemother. 2012;56:5076-5081.
Rodvold KA, Hope WW, Boyd SE. Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung. Curr Opin Pharmacol. 2017;36:114-123.
Rubenfeld GD. Confronting the frustrations of negative clinical trials in acute respiratory distress syndrome. Ann Am Thorac Soc. 2015;12 Suppl 1:S58-63.
Salerno SN, Edginton A, Cohen-Wolkowiez M, Hornik CP, Watt KM, Jamieson BD et al. Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid. CPT Pharmacometrics Syst Pharmacol. 2017;6:814-822.
Schaumann F, Borm PJ, Herbrich A, Knoch J, Pitz M, Schins RP, et al. Metal-rich ambient particles (particulate matter 2.5) cause airway inflammation in healthy subjects. Am J Respir Crit Care Med. 2004;170:898-903.
Scheraga RG, Abraham S, Grove LM, Southern BD, Crish JF, Perelas A, et al. TRPV4 Protects the Lung from Bacterial Pneumonia via MAPK Molecular Pathway Switching. J Immunol. 2020; 204:1310-1321.
Singh D, Siew L, Christensen J, Plumb J, Clarke GW, Greenaway S, et al. Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects. Eur J Clin Pharmacol. 2015;71:1175-84.
Spieth PM, Zhang H. Pharmacological therapies for acute respiratory distress syndrome. Curr Opin Crit Care. 2014;20:113-21. .
Thorneloe KS, Cheung M, Bao W, Alsaid H, Lenhard S, Jian M-Y,et al. An Orally Active TRPV4 Channel Blocker Prevents and Resolves Pulmonary Edema Induced by Heart Failure. Pulmonary edema. 2012;4:159ra148.
Yin J, Michalick L, Tang C, Tabuchi A, Goldenberg N, Dan Q,et al. Role of Transient Receptor Potential Vanilloid 4 in Neutrophil Activation and Acute Lung Injury. Am J Respir Cell Mol Biol. 2016;54:370-83.
Zielen S, Trischler J, Schubert R. Lipopolysaccharide challenge: immunological effects and safety in humans. Exp Review Clin Immunol. 2015;11:409-18.